Is EAE being turned in to a B cell disease as ocrelizumab gets nearer the clinic.
This study says that rather than have consistent disease severity in your experiments if you want to get your treatment to have a lesser effect, make sure you have a control score of mean 4, but if you want to show that your treatment makes things worse make sure your control group is mean 2:-)
Only kidding. It says that you have to induce your disease in a certain way do it with whole protein you get one thing do it with a peptide of the same protein you get a different thing. It has been argued that it is all to so with processing of antigen, but in this study it says if you block the target for natalizumab then B regulatory cells don't get into the CNS and have more severe disease, so does this tell us that the role of natalizumab is to block T cells because if the major action was on the B cell then would MS not get worse?. So more support for the role of T cells in MS. However, if you look at the disease profile it suggests that the influence is not on disease development but on disease inhibition once started.